Vaxcyte Launches $1B Dual Offering to Fund VAX-31 Commercial Push
PCVX sits 78% above its 52-week low of $39.87 on elevated volume (11× avg).
Summary
Vaxcyte is raising up to $1.15B through concurrent offerings of $500M in common stock/pre-funded warrants and $500M in convertible senior notes due 2032, with underwriter options for an additional $150M. The raise comes just hours after positive OPUS-1 Phase 3 data for VAX-31, its 31-valent pneumococcal vaccine candidate, and is earmarked for clinical development, manufacturing scale-up, and commercial launch preparation. This is a significant capital event for a company with a $11B market cap, and the timing suggests management is capitalizing on the data-driven stock momentum. The convertible notes add potential future dilution, but the proceeds extend the runway for a pivotal commercial launch. Pricing terms, including the conversion premium and interest rate, will be set at pricing and will determine the actual dilution impact.
Updates
· SEC 424B5 — The preliminary prospectus leaves the aggregate principal amount, interest rate, and conversion price blank, pending pricing.
· SEC 424B5 — The preliminary prospectus leaves the number of shares, offering price, and underwriting discounts blank, pending pricing.
At the time of this announcement, PCVX was trading at $71.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $39.87 to $90.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.